


**Desmopressin for reversal of Antiplatelet drugs in
Stroke due to Haemorrhage (DASH)**


EudraCT:2018-001904-12

PHARMACY MANUAL

Version 1.0, 8th January 2019

Chief Investigator: Professor Nikola Sprigg
Sponsor: University of Nottingham
Sponsor Reference:18040

Written by: (Print & sign)	Bernie Cook		Date: 5 th February 2019
Title	Lead Pharmacy Technician – Clinical Trials (NUH NHS Trust)		

Approved by: (Print & sign)	Sheila Hodgson		Date: 5 th February 2019
Title	Lead Pharmacist – Clinical Trials (NUH NHS Trust)		

Property of Nottingham University Hospitals NHS Trust
**May not be used, divulged, published or otherwise disclosed without the consent of the
Chief Investigator**

Applicability

This procedure applies to all pharmacy personnel at participating sites. Its purpose is to ensure that the processes of storing, labelling, ordering, dispensing accounting for and destroying IMP are carried out to the standard required for DASH and in accordance with the applicable ICH-GCP principles.

Responsibilities

All personnel carrying out study related activities should be listed on the DASH Authorised Personnel Log and be appropriately trained and familiar with the trial, its protocol and procedures.

For each site a lead pharmacist should be identified. This person will have overall responsibility for the study and will be required to sign a lead pharmacist declaration form and return this to the STU prior to the IMP being received at site